
26th October 2016

Healthcare

Transgene

Price EUR2.71

Bloomberg TNG FP TRNG PA Reuters 12-month High / Low (EUR) 3.8 / 2.3 Market Cap (EUR) 156 Ev (BG Estimates) (EUR) 213 Avg. 6m daily volume (000) 81.80 **3y EPS CAGR** -8.4% 1 M 3 M 6 M 31/12/15 Absolute perf. -5.8% 1.8% -6.8% 7.1% Healthcare -6.4% -9.9% -5.6% -12.9% DJ Stoxx 600 -0.7% 0.6% -1.0% -6.2% YEnd Dec. (EURm) 2015 2016e 2017e 2018e Sales 0.0 0.0 0.0 0.0 % change EBITDA -33.2 -25.8 -23.8 -26.0 EBIT -35.8 -35.1 -26.0 -28.1 2.1% 25.8% -8.2% % change Net income -37.9 -36.1 -27.0 -29.1 -7.9% % change 4.9% 25.1% 2015 2016e 2017e 2018e Operating margin NM NM NM NM NM Net margin NM NM NM ROE -142.8 379.2 74.0 <u>44</u> 4 ROCE -73.1 -70.5 -53.5 -58.6 Gearing 83.4 -604.3 -229.4 -170.9 (EUR) 2015 2016e 2017e 2018e EPS -0.98 -0.94 -0.70 -0.76 % change 4.9% 25.1% -7.9% P/E NS NS NS NS FCF yield (%) NM NM NM NM Dividends (EUR) 0.00 0.00 0.00 0.00 Div yield (%) NM NM NM NM NS EV/Sales NS NS NS EV/EBITDA NS NS NS NS



NS

NS

NS

NS

EV/EBIT

Strong newsflow ahead

Fair Value EUR5 (+85%)

CORPORATE

Now that the company is on the verge of securing a capital increase of c.EUR48m (of which 75% is garanteed by the Mérieux Institute), we would like to come back on some key short-term catalysts that are likely to support the stock in the coming months. We also stick to our FV of EUR5.0 since the risk-reward profile is attractive, in our view.

ANALYSIS

- PexaVEC: an improving momentum. The oncolytic virus class has benefited from various positive read-across analyses over the past few months. First, Amgen's Imlygic (talimogene laherparepvec) got approved both in the US and Europe for the treatment of adults with advanced melanoma. Second, some quite promising data in combination with ipilimumab have been published (ORR: c.50% in previously untreated patients with melanoma). Third, apart from Amgen and Merck, BMS and AstraZeneca also got their hands on molecules from this therapeutic family through acquisitions or collaboration agreements.
- Sillajen to be listed in Asia: a potential positive read-across in H2 16. Sillajen is said to consider an IPO on the KOSDAQ, and rumors say that the pre-money valuation could exceed USD1Bn (!). Such figure is too optimistic in our view, especially since the company retains solely a part of PexaVEC's rights... But there is a chance that the final number will be much higher than what the street currently retains for TNG's rights (BG EV: c.EUR150m).
- CSF1/CSF1R is one of the most attractive targets in the I-O field in our view. Its blockade is indeed thought to induce a strong modulation of the tumor microenvironment, and thus improve the reponse to PD-1/PD-L1 blockers (upregulation of PD-L1 and even CTLA-4, depletion of immune suppressive cells and notably TAMs, reprogramming of macrophage populations to support antitumor immunity). No doubt that this is one of the very reasons why BMS inked such a lucrative deal with Five Prime (up to USD1.74Bn payments, including an upfront amounted to USD350m) to get its hands on FPA008 (an anti-CSF1R mAb).
- TG3003 (anti-CSF1R) is another asset to be reckon with. We believe that big/mid pharmas lacking
 this type of molecule (e.g. Merck KGaA) could be interested in inking a licensing deal with TNG to
 improve/distinguish themselvesfrom the crowd... Especially since TG3003 might benefit from a
 differentiated mechanism of action (skewing of monocyte differentiation from M2-TAM towards
 dendritic cells, decreased production of IL-6, no blockade of ligand binding / non-cytotoxic).
 Further preclinical testing is to be done, but a licensing deal could be inked in the coming months
 should these preliminary data confirm TG3003's MoA.
- And of course don't forget TG4010. As stated in our previous comments, there is a strong
 rationale behind the combination of a cancer vaccine like TG4010 and an anti-PD-1 (the first one
 boosting the anti-cancer response, while the latter disinhibits it + potential upregulation of PD-L1
 associated with an increased release of IFN-gamma). And should the future efficacy data confirm
 these synergies (BG: 2017e), the inking of a licensing deal would be more likely, in our view.

VALUATION

• We reiterate our FV of EUR5.0. The risk-reward profile is attractive in our view, especially since 1/ our valuation (which is c.75% above the current share price) could be significantly increased if key upside scenarios play out; 2/ the downside will be limited by the raised cash along with the diversity of the pipeline.

NEXT CATALYSTS

H2 16: IPO of Sillajen, positive read-across for PexaVEC + Potential ou-licensing of TG3003.

Click here to download document

C

Analyst : Mickael Chane Du 33(0) 1 70 36 57 45 mchanedu@bryangarnier.com Sector Team : Eric Le Berrigaud Hugo Solvet

BRYAN, GARNIER & CO

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a
DUT	recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock
	will feature an introduction outlining the key reasons behind the opinion.

- NEUTRAL Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
- SELL Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 57.3%

NEUTRAL ratings 31.2%

SELL ratings 11.5%

Research Disclosure Legend

1	Bryan Garnier shareholding in IssuerBryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").		No
2	Issuer shareholding in Bryan GarnierThe Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.		No
3	Financial interest A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report		No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.		YES
6	5 Investment banking agreement A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement Issuer relating to the provision of investment banking services, or has in that period received payment promised payment in respect of such services.		YES
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	nuneration of analyst The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	YES
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

BRYAN, GARNIER & CO

London	Paris	New York	Geneva	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St. Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by the	Financial Conduct Authority (FCA) and		Regulated by the	Fax +91 11 2621 9062
Financial Conduct Authority	the Autorité de Contrôle prudential et de		FINMA	
(FCA)	resolution (ACPR)			

Important information

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This report has been prepared solely for informational purposes and is intended only for use by the designated recipient(s).

This report is non-independent research within the meaning of the FCA rules. This report is not being held out as an objective or independent explanation of the matters contained within it and has been sent to you for marketing purposes only and should not be treated as such. This report has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. Bryan Garnier & Co Limited is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This information was obtained from sources we believe to be reliable, but its accuracy is not guaranteed. All information is subject to change without notice. This does not constitute a solicitation or offer to buy or sell securities or any other instruments, or a recommendation with respect to any security or instrument mentioned herein. This is not a confirmation of terms of any transaction. No representations are made herein with respect to availability, pricing, or performance. Additional information available on request.

This document should only be read by those persons to whom it is addressed and is not intended to be relied upon by any person without subsequent written confirmation of its contents. If you have received this e-mail message in error, please destroy it and delete it from your computer. Any form of reproduction, dissemination, copying, disclosure, modification, distribution and/or publication of this e-mail message is strictly prohibited.

Please note that any views or opinions presented in this e-mail are solely those of the author and do not necessarily represent those of Bryan Garnier & Co Limited.

Finally, the recipient should check this e-mail and any attachments for the presence of viruses. Bryan Garnier & Co Limited accepts no liability for any damage caused by any virus transmitted by this email.